Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
127
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Inflammatory Response01:28

Inflammatory Response

2.0K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.0K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

162
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
162

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IL-6-induced C/EBPα drives follicular regulatory T cell differentiation to regulate humoral immunity in mice.

Nature communications·2026
Same author

Network-based machine learning to identify biomarkers for systemic lupus erythematosus.

BMC biology·2026
Same author

Noble Metal Aerogels: Synthesis and Application as Support-Free Anode Electrocatalysts for Ethanol Electro-Oxidation.

Gels (Basel, Switzerland)·2026
Same author

Micheliolide ameliorates colon cancer cachexia by modulating gut microbiota-immune signaling via Phocaeicola vulgatus enrichment.

Microbiome·2026
Same author

Conserved noncoding sequence-9 regulates NFATc1-mediated IL-10 expression in B cells to control inflammatory responses.

Science advances·2026
Same author

Real-Time Assessment of Black Carbon Peaks Among Workers Exposed to Diesel Engine Exhaust Emissions.

Safety and health at work·2026

Related Experiment Video

Updated: Jun 29, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

827

Probiotic Consortium Confers Synergistic Anti-Inflammatory Effects in Inflammatory Disorders.

Changhon Lee1, Seung Won Kim1, Ravi Verma2

  • 1Department of Life Sciences, POSTECH Biotech Center, Pohang University of Science and Technology (POSTECH), Pohang 37673, Republic of Korea.

Nutrients
|March 28, 2024
PubMed
Summary

Bacterial consortia, like MPRO, show greater therapeutic effects than single strains for inflammatory diseases. This study highlights the potential of MPRO in dampening inflammation and improving gut health for conditions such as atopic dermatitis and colitis.

Keywords:
atopic dermatitisinflammatory colitismicrobiotaprobiotic consortiumregulatory T cell

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.3K
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

47.4K

Related Experiment Videos

Last Updated: Jun 29, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

827
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.3K
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

47.4K

Area of Science:

  • Microbiology
  • Immunology
  • Gastroenterology

Background:

  • Gut microbiota composition impacts immune function and disease development, including inflammatory and allergic disorders.
  • Microbiota-based therapeutics are promising but optimal strategies, particularly comparing bacterial consortia to single species, require further research.

Purpose of the Study:

  • To compare the therapeutic efficacy of the bacterial consortium MPRO (Lactiplantibacillus plantarum HY7712, Bifidobacterium animalis ssp. lactis HY8002, Lacticaseibacillus casei HY2782) against its individual components.
  • To investigate the immunomodulatory effects of MPRO in experimental models of inflammatory diseases.

Main Methods:

  • Experimental models of atopic dermatitis and inflammatory colitis were used.
  • The effects of MPRO and its individual strains on immune responses and gut microbiota were assessed.
  • Changes in intestinal dendritic cells and regulatory T cells were analyzed.

Main Results:

  • MPRO demonstrated superior therapeutic efficacy compared to single strains in models of atopic dermatitis and inflammatory colitis.
  • MPRO administration effectively reduced inflammatory responses and modulated the gut microbial landscape.
  • MPRO increased intestinal CD103+CD11b+ dendritic cells, promoting regulatory T cell induction and inflammation suppression.

Conclusions:

  • Bacterial consortia, exemplified by MPRO, are more effective than single strains for treating inflammatory disorders.
  • MPRO holds significant potential for clinical application in managing inflammatory conditions through immune modulation and gut microbiota alteration.